Skip to content
‹ Back to IndustriesHealthcare

More Nations Pause Use of AstraZeneca Shot

The vaccination program in Europe has sunk further into disarray. The countries that are suspending the use of the AstraZeneca Plc. shot are rising. Germany, France, Italy and Portugal are just the latest countries to pause the use of the vaccine pending a further assessment by the European Medicines Agency. Bloomberg’s Maria Tadeo reports on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The vaccination program in Europe has sunk further into disarray. The countries that are suspending the use of the AstraZeneca Plc. shot are rising. Germany, France, Italy and Portugal are just the latest countries to pause the use of the vaccine pending a further assessment by the European Medicines Agency. Bloomberg’s Maria Tadeo reports on “Bloomberg Daybreak: Europe.”

“This is a PR nightmare for AstraZeneca. It’s a huge blow for that vaccine. And just the communications around it just really very much all over the place in Europe.” – Maria Tadeo

—

MANUS: What’s precipitated this caution, rising caution, by the heart of Europe? Good morning.

MARIA: Good morning Manus. Really it was that decision from Germany yesterday to suspend AstraZeneca. They worry about the blood clots. They say they want to figure out if this is a direct side effect from the AstraZeneca vaccine. And it’s the Germans taking that decision, very controversial decision yesterday, that really precipitated this domino effect from the French, from the Italians, from the Spanish. And if you move away from that, I guess you could say it’s legitimate to review a vaccine if there’s issues or concerns around it. The problem here really has been the communications, Manus. This has been all over the place for a week now. The European public very much whiplashed by a number of information that contradicts each other. And I would also say when you look at the statements still from the regulator the European Medicines Agency, still singing, still reiterating, ‘we still believe the benefits of the vaccine would outstrip the risks.’ So this is of course an issue about the vaccine. It’s about those concerns which may be, I want to stress, very legitimate on the blood clots. But really this is a PR nightmare for AstraZeneca. It’s a huge blow for that vaccine. And just the communications around it just really very much all over the place in Europe.

ANNMARIE: Right Maria. Some are suggesting this is a much a political decision as it is scientific. What happens next. I know there’s a number of meetings coming up this week.

MARIA: Yes Annmarie, and look, Emmanuel Macron yesterday said he was suspending the vaccine and he would do so until today and that he wanted to see further clarity from the European Medicines Agency. Now as I said just yesterday, the EMEA, the head of the European Medicines Agency vaccine unit, he was still repeating that he didn’t really see a problem with AstraZeneca. Nonetheless we know that there’s also a health ministers meeting happening today and that on Thursday there will be a review by the European Medicines Agency. Now at that point it could decide to pull that vaccine altogether or it could reiterate that message that it is still okay to use it for public health. But the question at that point, and this is really the question in Europe, is whether or not the damage here, the reputational damage on AstraZeneca, has been done already. We have seen many anecdotal evidence that when it comes to the take up, AstraZeneca is much more problematic than any other vaccine that’s on the market in Europe so far, Annmarie.

*Bloomberg contributed to this article.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512